Progyny, Inc. (NASDAQ:PGNY) Shares Acquired by Victory Capital Management Inc.

Victory Capital Management Inc. grew its stake in shares of Progyny, Inc. (NASDAQ:PGNY) by 56.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 113,336 shares of the company’s stock after buying an additional 41,035 shares during the quarter. Victory Capital Management Inc. owned about 0.13% of Progyny worth $1,900,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the stock. Quarry LP boosted its position in shares of Progyny by 1,900.0% during the 2nd quarter. Quarry LP now owns 880 shares of the company’s stock valued at $25,000 after purchasing an additional 836 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Progyny in the 2nd quarter valued at approximately $44,000. Mendota Financial Group LLC bought a new position in shares of Progyny in the 3rd quarter valued at approximately $56,000. Cambridge Trust Co. bought a new position in Progyny in the 1st quarter worth $95,000. Finally, 1620 Investment Advisors Inc. bought a new position in Progyny in the 2nd quarter worth approximately $97,000. 94.93% of the stock is owned by institutional investors and hedge funds.

Progyny Trading Up 3.1 %

Shares of NASDAQ PGNY opened at $15.44 on Monday. The company has a market capitalization of $1.31 billion, a P/E ratio of 26.62, a P/E/G ratio of 1.73 and a beta of 1.44. The stock has a 50 day moving average of $16.40 and a 200-day moving average of $22.61. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $42.08.

Progyny (NASDAQ:PGNY) last announced its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The business had revenue of $286.63 million for the quarter, compared to analyst estimates of $296.85 million. During the same quarter in the previous year, the company earned $0.16 EPS. The business’s revenue for the quarter was up 2.0% on a year-over-year basis. Analysts predict that Progyny, Inc. will post 0.58 EPS for the current fiscal year.

Analyst Ratings Changes

PGNY has been the subject of a number of research reports. JPMorgan Chase & Co. reduced their price objective on Progyny from $31.00 to $22.00 and set an “overweight” rating for the company in a research report on Thursday, September 19th. Canaccord Genuity Group reduced their price objective on shares of Progyny from $18.00 to $17.00 and set a “hold” rating on the stock in a research note on Wednesday, November 13th. Jefferies Financial Group decreased their price objective on shares of Progyny from $31.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, September 19th. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 target price on shares of Progyny in a research note on Tuesday, October 1st. Finally, JMP Securities downgraded Progyny from an “outperform” rating to a “market perform” rating in a report on Thursday, September 19th. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $25.42.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.